James reaffirmed its Outperform rating and $175.00 price target for Natera (NASDAQ:NTRA), following updates to oncology guidelines that could impact the company's cancer testing product, Signatera.

Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which ...

Canopy reported revenues of C$74.8-million in the quarter, up 18.7 per cent from the previous quarter and ahead of consensus ...

In a report released on February 6, Timothy Hoff from Canaccord Genuity maintained a Buy rating on WA1 Resources Ltd (WA1 – Research Report), ...

In a report released on February 7, James Bullen from Canaccord Genuity maintained a Sell rating on Beach Energy Limited (BEPTF – Research ...

Stingray is looking at several ‘meaningful, larger tuck-in’ acquisitions worth up to $100-million, analyst says ...